Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 4
1983 2
1984 1
1985 1
1986 4
1988 4
1989 2
1990 3
1991 2
1992 2
1993 1
1995 3
2002 1
2005 4
2006 4
2007 4
2008 2
2009 1
2010 2
2011 7
2012 5
2013 1
2014 3
2015 3
2016 7
2017 3
2018 9
2019 5
2020 9
2021 10
2022 11
2023 27
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. Simuni T, et al. Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Lancet Neurol. 2024. PMID: 38267190 Review.
This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal alpha-synuclein (n-alphasyn) in human beings during li …
This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of t …
Lung targeted liposomes for treating ARDS.
Arber Raviv S, Alyan M, Egorov E, Zano A, Harush MY, Pieters C, Korach-Rechtman H, Saadya A, Kaneti G, Nudelman I, Farkash S, Flikshtain OD, Mekies LN, Koren L, Gal Y, Dor E, Shainsky J, Shklover J, Adir Y, Schroeder A. Arber Raviv S, et al. J Control Release. 2022 Jun;346:421-433. doi: 10.1016/j.jconrel.2022.03.028. Epub 2022 Mar 28. J Control Release. 2022. PMID: 35358610 Free PMC article.
The liposomal lipid composition (primarily DPPC) was optimized to mimic the lung surfactant composition, and the drug loading process of both methylprednisolone (MPS), a steroid, and N-acetyl cysteine (NAC), a mucolytic agent, reached an encapsulation efficiency of 98% and …
The liposomal lipid composition (primarily DPPC) was optimized to mimic the lung surfactant composition, and the drug loading process of bot …
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, Arad M. Arow M, et al. Cardiovasc Diabetol. 2020 Jan 10;19(1):7. doi: 10.1186/s12933-019-0980-4. Cardiovasc Diabetol. 2020. PMID: 31924211 Free PMC article.
Dapagliflozin (1.5 mg/kg/day) was administered concomitantly in drinking water. Male homozygous, 12-14 weeks old WT or db/db mice (n = 4-8/group), were used for the experiments. Isolated cardiomyocytes were exposed to glucose (17.5-33 mM) and treated with Dapagliflozin in …
Dapagliflozin (1.5 mg/kg/day) was administered concomitantly in drinking water. Male homozygous, 12-14 weeks old WT or db/db mice (n …
Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.
Nudelman KNH, Jackson T, Rumbaugh M, Eloyan A, Abreu M, Dage JL, Snoddy C, Faber KM, Foroud T, Hammers DB; DIAN/DIAN-TU Clinical/Genetics Committee; Taurone A, Thangarajah M, Aisen P, Beckett L, Kramer J, Koeppe R, Kukull WA, Murray ME, Toga AW, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez M, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium. Nudelman KNH, et al. Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S64-S73. doi: 10.1002/alz.13482. Epub 2023 Oct 6. Alzheimers Dement. 2023. PMID: 37801072 Review.
Toward this goal, LEADS participants are screened for known pathogenic variants. METHODS: LEADS amyloid-positive early-onset Alzheimer's disease (EOAD) or negative early-onset non-AD (EOnonAD) cases were whole exome sequenced (N = 299). ...Rare variants were not enr …
Toward this goal, LEADS participants are screened for known pathogenic variants. METHODS: LEADS amyloid-positive early-onset Alzheimer's …
A robust pipeline for rapid production of versatile nanobody repertoires.
Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, Rout MP. Fridy PC, et al. Nat Methods. 2014 Dec;11(12):1253-60. doi: 10.1038/nmeth.3170. Epub 2014 Nov 2. Nat Methods. 2014. PMID: 25362362 Free PMC article.
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
Barrette AM, Ronk H, Joshi T, Mussa Z, Mehrotra M, Bouras A, Nudelman G, Jesu Raj JG, Bozec D, Lam W, Houldsworth J, Yong R, Zaslavsky E, Hadjipanayis CG, Birtwistle MR, Tsankova NM. Barrette AM, et al. Neuro Oncol. 2022 May 4;24(5):694-707. doi: 10.1093/neuonc/noab244. Neuro Oncol. 2022. PMID: 34657158 Free PMC article.
Here, we use the FDA-approved drug and small molecule Hippo inhibitor Verteporfin (VP) to target YAP-TEAD activity, known to mediate convergent aspects of tumor invasion/metastasis, and assess the drug's efficacy and survival benefit in GBM models. METHODS: Up to 8 low-pas …
Here, we use the FDA-approved drug and small molecule Hippo inhibitor Verteporfin (VP) to target YAP-TEAD activity, known to mediate converg …
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R; Alzheimer’s Disease Neuroimaging Initiative; La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R. Bocancea DI, et al. Brain. 2023 Sep 1;146(9):3719-3734. doi: 10.1093/brain/awad100. Brain. 2023. PMID: 36967222 Free PMC article.
In this multicentre study, we included 366 amyloid-beta-positive individuals with mild cognitive impairment or Alzheimer's disease dementia with baseline 18F-flortaucipir-PET and longitudinal cognitive assessments. ...In this longitudinal study of clinically impaired indiv …
In this multicentre study, we included 366 amyloid-beta-positive individuals with mild cognitive impairment or Alzheimer's disease de …
Learning slopes in early-onset Alzheimer's disease.
Hammers DB, Nemes S, Diedrich T, Eloyan A, Kirby K, Aisen P, Kramer J, Nudelman K, Foroud T, Rumbaugh M, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Weintraub S, Wingo TS, Wolk DA, Wong B, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium. Hammers DB, et al. Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S19-S28. doi: 10.1002/alz.13159. Epub 2023 May 27. Alzheimers Dement. 2023. PMID: 37243937
The current study aimed to highlight the sensitivity of learning slopes to discriminate disease severity in cognitively normal participants and those diagnosed with early-onset dementia with and without beta-amyloid positivity METHOD: Data from 310 participants in the Longitudina …
The current study aimed to highlight the sensitivity of learning slopes to discriminate disease severity in cognitively normal participants …
The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort.
Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T, Ghetti B, Griffin P, Hammers D, Jack CR Jr, Kramer JH, Iaccarino L, Joie R, Mundada NS, Koeppe R, Kukull WA, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC; LEADS Consortium. Touroutoglou A, et al. Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S74-S88. doi: 10.1002/alz.13466. Epub 2023 Oct 18. Alzheimers Dement. 2023. PMID: 37850549
INTRODUCTION: Magnetic resonance imaging (MRI) research has advanced our understanding of neurodegeneration in sporadic early-onset Alzheimer's disease (EOAD) but studies include small samples, mostly amnestic EOAD, and have not focused on developing an MRI biomarker. METH …
INTRODUCTION: Magnetic resonance imaging (MRI) research has advanced our understanding of neurodegeneration in sporadic early-onset Alzheime …
Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT, Iaccarino L, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga AW, Touroutoglou A, Vemuri P, Atri A, Beckett LA, Day GS, Graff-Radford NR, Duara R, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack KB, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium. Dage JL, et al. Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S115-S125. doi: 10.1002/alz.13399. Epub 2023 Jul 25. Alzheimers Dement. 2023. PMID: 37491668
INTRODUCTION: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early-onset Alzheimer's disease (EOAD). ...
INTRODUCTION: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteris …
143 results